What were Kringle Pharma, Inc.'s latest financial results?

Kringle Pharma, Inc. (4884.T) reported its latest results in an earnings disclosure filed with the Tokyo Stock Exchange. The full English translation is in the article above.

Where can I read Kringle Pharma, Inc.'s earnings disclosure in English?

Pulse News Wire provides real-time English translations of Kringle Pharma, Inc.'s TDNet filings, including this earnings report.

How quickly are Kringle Pharma, Inc.'s TSE filings translated into English?

Pulse News Wire translates Tokyo Stock Exchange disclosures typically within 5 minutes of filing, covering all 4,436 listed companies including Kringle Pharma, Inc..

| API Access | |

Pulse News Wire translates Japanese corporate disclosures filed with the Tokyo Stock Exchange's TDNet system into clear, structured English for institutional investors, hedge funds, and asset managers. Every article on this page is derived directly from an official TDNet filing: earnings reports, M&A announcements, share buybacks, dividend declarations, and governance changes. Japanese corporate governance is governed by the Companies Act and the Financial Instruments and Exchange Act; timely translation of these disclosures gives cross-border investors faster access to Tokyo-listed disclosures.

This corporate disclosure from Kringle Pharma, Inc. was processed by Pulse News Wire on May 11, 2026. It represents a primary source document for Japanese Earnings sector intelligence, translated directly from an official filing submitted to the Tokyo Stock Exchange TDNet system.

Kringle Pharma Reports Earnings Results

TOKYO, May 11 (Pulse News Wire) – Kringle Pharma, Inc. (4884.T) reported non-consolidated results for Q2 FY2026 (ending September 2026). Operating profit was ¥515 million. net profit was ¥516 million.

View all Kringle Pharma, Inc. disclosures →

Kringle Pharma, Inc. [4884.T]

TOKYO, May 11 (Pulse News Wire) – Kringle Pharma, Inc. (4884.T) reported non-consolidated results for Q2 FY2026 (ending September 2026).

Operating profit was ¥515 million. net profit was ¥516 million.

Total assets stood at ¥2.0 billion with an equity ratio of 45.9%. The full-year forecast for the current fiscal year is revenue of ¥330 million (+360.4%).

Financial results — FY2026/9 (consolidated)

Metric	Current	YoY
Revenue	¥36M	+2.2%
Operating profit	¥-515M	n/a
Net profit	¥-516M	n/a

Next period forecast

Revenue

¥332M

+360.4%

Op. profit

¥-1,018M

n/a

Net profit

¥-1,020M

n/a

Source: TDNet filing · Figures in millions of yen

Original Disclosure (PDF)

🟢 Confidence: High AI-translated content.

About This Source

Pulse News Wire is a specialized financial intelligence platform dedicated to the translation and analysis of Tokyo Stock Exchange (TDNet) filings for global institutional investors. Every disclosure published on Pulse News Wire is derived directly from an official TDNet primary source document and processed typically within 5 minutes of filing using validated AI translation, providing cross-border investors with timely, structured access to Japanese corporate events.

What We Are Not

Pulse News Wire is a translation and distribution service for primary source documents. We do not provide investment advice, price targets, earnings estimates, or analyst commentary. Our articles reflect the content of the original filing and nothing more.

Pulse News Wire is not affiliated with, endorsed by, or in any way connected to the Tokyo Stock Exchange, Japan Exchange Group (JPX), TDNet, or any company whose disclosures appear on this site. We are an independent translation service. The companies we cover have not reviewed, approved, or contributed to any content published here.

Kringle Pharma Reports Earnings Results

Related Disclosures